Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.
Decision support systems
Non-small-cell lung cancer
Surveys and questionnaires
Journal
Journal of cancer education : the official journal of the American Association for Cancer Education
ISSN: 1543-0154
Titre abrégé: J Cancer Educ
Pays: England
ID NLM: 8610343
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
28
1
2019
medline:
12
1
2021
entrez:
28
1
2019
Statut:
ppublish
Résumé
Treatment decision-making for patients with incurable non-small cell lung cancer (NSCLC) is complex due to the rapidly increasing number of treatments and discovery of new biomarkers. Decision support systems (DSS) could assist thoracic oncologists (TO) weighing of the pros and cons of treatments in order to arrive at an evidence-based and personalized treatment advice. Our aim is to inventory (1) TO's needs with regard to DSS in the treatment of incurable (stage IIIB/IV) NSCLC patients, and (2) preferences regarding the development of future tools in this field. We disseminated an online inventory questionnaire among all members of the Section of Oncology within the Society of Physicians in Chest Medicine and Tuberculosis. Telephone interviews were conducted to better contextualize the findings from the questionnaire. In total, 58 TO completed the questionnaire and expressed a need for new DSS. They reported that it is important for tools to include genetic and immune markers, to be sufficiently validated, regularly updated, and time-efficient. Also, future DSS should incorporate multiple treatment options, integrate estimates of toxicity, quality of life and cost-effectiveness of treatments, enhance communication between caregivers and patients, and use IT solutions for a clear interface and continuous updating of tools. With this inventory among Dutch TO, we summarized the need for new DSS to aid treatment decision-making for patients with incurable NSCLC. To meet the expressed needs, substantial additional efforts will be required by DSS developers, above already existing tools.
Identifiants
pubmed: 30685832
doi: 10.1007/s13187-019-1471-8
pii: 10.1007/s13187-019-1471-8
pmc: PMC7075822
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-351Références
American Cancer Society [updated 01-07-2016; cited 2016 23-02-2016]. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf . Accessed 1 July 2016
World Health Organization Cancer Fact sheet [updated 01-02-2015; cited 2016 23-02-2016]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ . Accessed 23 Feb 2016
Incidentie-, prevalentie- en sterftecijfers: Nederlandse Kankerregistratie beheerd door IKNL; 2016 [updated 04-02-2016; cited 2016 23-02-2016]. Available from: http://www.cijfersoverkanker.nl . Accessed 4 Feb 2016
Revesz D, Engelhardt EG, Tamminga JJ, Schramel F, Onwuteaka-Philipsen BD, van de Garde EMW et al (2017) Decision support systems for incurable non-small cell lung cancer: a systematic review. BMC Med Inform Decis Mak 17(1):144
doi: 10.1186/s12911-017-0542-1
Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA (2008) A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 3(6):590–598
doi: 10.1097/JTO.0b013e3181729299
Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2012) Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 7(9):1361–1368
doi: 10.1097/JTO.0b013e318260e106
Tseng YD, Krishnan MS, Sullivan AJ, Jones JA, Chow E, Balboni TA (2013) How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. Int J Radiat Oncol Biol Phys 87(3):471–478
doi: 10.1016/j.ijrobp.2013.06.2046
Chiu N, Chiu L, Lutz S, Zhang N, Lechner B, Pulenzas N, Popovic M, DeAngelis C, Milakovic M, Chow R, Chow E (2015) Incorporation of life expectancy estimates in the treatment of palliative care patients receiving radiotherapy: treatment approaches in light of incomplete prognostic models. Ann Palliat Med 4(3):162–168
pubmed: 26231813
Hallen SA, Hootsmans NA, Blaisdell L, Gutheil CM, Han PK (2015) Physicians’ perceptions of the value of prognostic models: the benefits and risks of prognostic confidence. Health Expect 18(6):2266–2277
doi: 10.1111/hex.12196
Engelhardt EG, Pieterse AH, van Duijn-Bakker N, Kroep JR, de Haes HC, Smets EM et al (2015) Breast cancer specialists’ views on and use of risk prediction models in clinical practice: a mixed methods approach. Acta Oncol 54(3):361–367
doi: 10.3109/0284186X.2014.964810
Langton JM, Blanch B, Pesa N, Park JM, Pearson SA (2013) How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey. BMC Med Inform Decis Mak 13:82
doi: 10.1186/1472-6947-13-82
Bansal P, Osman D, Gan GN, Simon GR, Boumber Y (2016) Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol 6:112
pubmed: 27200298
pmcid: 4854869
Chen JY, Cheng YN, Han L, Wei F, Yu WW, Zhang XW, Cao S, Yu JP (2015) Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biol Med 12(2):126–139
pubmed: 26175928
pmcid: 4493374
Shea M, Costa DB, Rangachari D (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10(2):113–129
doi: 10.1177/1753465815617871
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R (2015) Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 10(1 Suppl 1):S1–S63
doi: 10.1097/JTO.0000000000000405
Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR (2015) Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 21(10):2236–2243
doi: 10.1158/1078-0432.CCR-14-3039
Hall RD, Le TM, Haggstrom DE, Gentzler RD (2015) Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 4(5):515–523
pubmed: 26629420
pmcid: 4630516
Herzberg B, Campo MJ, Gainor JF (2016) Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist
Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, Tan DSW (2016) Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 17(8):e347–e362
doi: 10.1016/S1470-2045(16)30123-1
Nederlandse Landelijke richtlijn Niet-kleincellig longcarcinoom, Versie: 2.3: Landelijke Werkgroep Longtumoren; 2015 [updated 19-12-2015; cited 2016 23-02-2016]. Available from: http://www.oncoline.nl/niet-kleincellig-longcarcinoom . Accessed 23 Feb 2016
Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33(23):2563–2577
doi: 10.1200/JCO.2015.61.6706
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39
doi: 10.1093/annonc/mdu199
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016) NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw 14(3):255–264
doi: 10.6004/jnccn.2016.0031
Downing GJ, Boyle SN, Brinner KM, Osheroff JA (2009) Information management to enable personalized medicine: stakeholder roles in building clinical decision support. BMC Med Inform Decis Mak 9:44
doi: 10.1186/1472-6947-9-44
Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F (2015) The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today 20(12):1433–1438
doi: 10.1016/j.drudis.2015.05.013
Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2016
Finlayson SG, Levy M, Reddy S, Rubin DL (2016) Toward rapid learning in cancer treatment selection: an analytical engine for practice-based clinical data. J Biomed Inform 60:104–113
doi: 10.1016/j.jbi.2016.01.005